CA Patent

CA2863723C — 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors

Assigned to Merck Patent GmbH · Expires 2020-09-22 · 6y expired

What this patent protects

Spiro triazolopyrazine compounds of the formula l in which R1 and R2 have the meanings defined herein, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and/or systemic lupus.

USPTO Abstract

Spiro triazolopyrazine compounds of the formula l in which R1 and R2 have the meanings defined herein, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and/or systemic lupus.

Drugs covered by this patent

Patent Metadata

Patent number
CA2863723C
Jurisdiction
CA
Classification
—
Expires
2020-09-22
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.